Propofol has been proved to be more favorable in breast cancer surgery than volatile general anesthetics (sevoflurane) in biomarker studies: a better inhibition on VEGF-C and TGF-β, more activated natural killer cells and higher cancer cell apoptosis. This evidence concerns the gene TGFB1 and breast carcinoma.